-
Company Profile
Ideaya Biosciences Inc – Company Profile
Ideaya Biosciences Inc (Ideaya) is a precision medicine company that develops oncology therapeutics. The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s...
Add to Basket -
Product Insights
Net Present Value Model: Bryostatin-1
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Bryostatin-1 Drug Details Bryostatin-1 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – REC-3599
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry REC-3599 Drug Details REC-3599 is under development for the treatment of Tay-Sachs disease or...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AR-13503 SR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AR-13503 SR Drug Details AR-13503 is under development for the treatment of wet age-related...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bryostatin-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Bryostatin-1 Drug Details Bryostatin-1 is under development for the treatment of Alzheimer's disease, multiple...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tigilanol tiglate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tigilanol tiglate Drug Details Tigilanol tiglate (EBC-46) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – APH-0812
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry APH-0812 Drug Details APH-0812 is under development for the treatment of HIV-1 latency. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – APH-0703
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry APH-0703 Drug Details APH-0703 is under development for the treatment of Alzheimer's disease and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – sotrastaurin acetate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry sotrastaurin acetate Drug Details Sotrastaurin acetate (AEB071) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – enzastaurin hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry enzastaurin hydrochloride Drug Details Enzastaurin hydrochloride (LY-317615.HCl) is under development for the treatment of...